Literature DB >> 11737582

Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.

K E White1, G Carn, B Lorenz-Depiereux, A Benet-Pages, T M Strom, M J Econs.   

Abstract

BACKGROUND: The gene for the renal phosphate wasting disorder autosomal-dominant hypophosphatemic rickets (ADHR) is FGF23, which encodes a secreted protein related to the fibroblast growth factors (FGFs). We previously detected missense mutations R176Q, R179W, and R179Q in FGF23 from ADHR kindreds. The mutations replace R residues within a subtilisin-like proprotein convertase (SPC) cleavage site 176RHTR-179 (RXXR motif). The goal of these studies was to determine if the ADHR mutations lead to protease resistance of FGF-23.
METHODS: The ADHR mutations were introduced into human FGF-23 cDNA clones with or without an N-terminal FLAG tag by site-directed mutagenesis and were transiently transfected into HEK293 cells. Protein expression was determined by Western analyses.
RESULTS: Antibodies directed toward the C-terminal portion of FGF-23 revealed that the native FGF-23 protein resolved as 32 kD and 12 kD species in HEK293 conditioned media; however, the three mutated proteins were detected only as the 32 kD band. An N-terminal FLAG-tagged native FGF-23 resolved as two bands of 36 kD and 26 kD when detected with a FLAG antibody, whereas the R176Q mutant resolved primarily as the 36 kD protein species. Cleavage of FGF-23 was not enhanced by extracellular incubation of FGF-23 with HEK293 cells. Native and mutant FGF-23s bound heparin.
CONCLUSIONS: FGF-23 proteins containing the ADHR mutations are secreted, and produce polypeptides less sensitive to protease cleavage than wild-type FGF-23. Therefore, the ADHR mutations may protect FGF-23 from proteolysis, thereby potentially elevating circulating concentrations of FGF-23 and leading to phosphate wasting in ADHR patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11737582     DOI: 10.1046/j.1523-1755.2001.00064.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  176 in total

Review 1.  The expanding family of hypophosphatemic syndromes.

Authors:  Thomas O Carpenter
Journal:  J Bone Miner Metab       Date:  2011-12-14       Impact factor: 2.626

Review 2.  Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Authors:  Emily G Farrow; Erik A Imel; Kenneth E White
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-10       Impact factor: 4.098

3.  A systematic study of site-specific GalNAc-type O-glycosylation modulating proprotein convertase processing.

Authors:  Katrine Ter-Borch Gram Schjoldager; Malene B Vester-Christensen; Christoffer K Goth; Thomas Nordahl Petersen; Søren Brunak; Eric P Bennett; Steven B Levery; Henrik Clausen
Journal:  J Biol Chem       Date:  2011-09-20       Impact factor: 5.157

Review 4.  Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.

Authors:  L Darryl Quarles
Journal:  Nat Rev Endocrinol       Date:  2012-01-17       Impact factor: 43.330

Review 5.  FGF23 and PTH--double agents at the heart of CKD.

Authors:  Justin Silver; Mariano Rodriguez; Eduardo Slatopolsky
Journal:  Nephrol Dial Transplant       Date:  2012-03-23       Impact factor: 5.992

6.  Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor.

Authors:  Regina Goetz; Mutsuko Ohnishi; Serkan Kir; Hiroshi Kurosu; Lei Wang; Johanne Pastor; Jinghong Ma; Weiming Gai; Makoto Kuro-o; Mohammed S Razzaque; Moosa Mohammadi
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

Review 7.  Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease.

Authors:  Nobuyuki Itoh; David M Ornitz
Journal:  J Biochem       Date:  2010-10-12       Impact factor: 3.387

8.  Sustained Klotho delivery reduces serum phosphate in a model of diabetic nephropathy.

Authors:  Julia M Hum; Linda M O'Bryan; Arun K Tatiparthi; Erica L Clinkenbeard; Pu Ni; Martin S Cramer; Manoj Bhaskaran; Robert L Johnson; Jonathan M Wilson; Rosamund C Smith; Kenneth E White
Journal:  J Appl Physiol (1985)       Date:  2019-01-03

9.  Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.

Authors:  Andrew C Karaplis; Xiuying Bai; Jean-Pierre Falet; Carolyn M Macica
Journal:  Endocrinology       Date:  2012-10-04       Impact factor: 4.736

10.  A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.

Authors:  Shoji Ichikawa; Erik A Imel; Mary L Kreiter; Xijie Yu; Donald S Mackenzie; Andrea H Sorenson; Regina Goetz; Moosa Mohammadi; Kenneth E White; Michael J Econs
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.